Navigation Links
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
Date:3/9/2010

"Morbidities and organ loss due to CMV have become a significant medical issue as the frequency of organ transplantation has increased and new immunosuppressive regimes have been introduced," said George Painter, Ph.D., President and Chief Executive Officer.  "CMX001 has demonstrated broad-spectrum activity in preclinical tests against double-stranded DNA viruses - including CMV - and has been well-tolerated to date among volunteers and patients.  We believe that with this combination of potent antiviral activity and tolerability, CMX001 will prove to be a powerful new treatment option for the transplant population and their physicians."

The Phase 2 clinical study is being conducted at approximately 25 leading academic and medical research centers in the United States.  Enrollment in the study is under way and will include approximately 120 patients.  Study participants will receive CMX001 once weekly following stem cell engraftment through post-transplant week 13, and will be monitored for CMV disease and viremia.  Participants will also be monitored for other dsDNA viruses susceptible to CMX001, including adenovirus, BK virus, and Epstein Barr virus.  Safety assessments will be conducted throughout the study.  

About CMX001


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
2. Chimerix to Present at Two Upcoming Investor Conferences
3. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
4. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
5. ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
6. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
10. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
11. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company ... results of a Phase 2b trial for Empatic(TM) on Wednesday, ... will be followed by a live webcast and conference call ... the call and webcast to discuss the results of this ...
... Pharmaceutical Major, Lupin Ltd. announced today the acquisition of ... mg). Lupin acquired the product from Oscient Pharmaceuticals on ... Court. Antara recorded net sales of US $ 70 ... $ 38.61 million for the product and related assets inclusive ...
Cached Medicine Technology:Lupin Expands Branded Play 2Lupin Expands Branded Play 3
(Date:7/11/2014)... records to understand the best available treatment for patients, ... and less costly for taxpayers than the existing clinical ... Professor van Staa, carried out while he was a ... who is now based at The University of Manchester,s ... ( HTA ) today (Friday 11 July) looked ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... the risk for stroke, a new study suggests. The ... a stroke or a transient ischemic attack (TIA) by ... or TIA risk by 59 percent. And hostility doubled the ... by a temporary blockage of blood flow to the brain. ...
(Date:7/11/2014)... conducted at Aarhus University has revealed that people who ... only half as likely as their urban counterparts to ... and Crohn,s disease. The study findings have recently been ... , "It is extremely exciting that we can now ... classic inflammatory diseases appear to depend on the environment ...
(Date:7/11/2014)... As reported by Forbes in the article Robert Downey ... (6/30), Indino Downey has reportedly been arrested after being ... with. His father, well-known actor Robert Downey Jr. believes ... may have something to do with his addiction struggles. ... and 1990s for substance abuse before finally getting clean ...
(Date:7/11/2014)... July 11, 2014 Having experienced mental illness ... member of mental hospital staff, Roger Grainger gives readers an ... in his new book, “You Never Get Out.” , According ... the United Kingdom will experience some kind of mental health ... still needs to take a look at the way mental ...
Breaking Medicine News(10 mins):Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Growing up on a livestock farm halves the risk of inflammatory bowel diseases 2Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2
... for "tennis elbow" but needs to be injected properly ... CMAJ ( Canadian Medical Association Journal ) ... a randomized controlled trial of 48 patients, was performed ... University of Medical Sciences that serves patients from all ...
... HACKENSACK, N.J. (April 26, 2010, 4 p.m. EDT) Myelodysplastic syndromes ... are nearly five times more common in seniors than previously ... John Theurer Cancer Center at Hackensack University Medical Center. ... patients are at much higher risk for heart attack, diabetes ...
... predict which are most likely to be good candidates ... News) -- U.S. researchers have developed a new tool ... potential organ donors, a development that could potentially boost ... damage are often good candidates for organ donation when ...
... diabetes now widespread, CDC survey finds , MONDAY, April ... adults have either high blood pressure, high cholesterol or ... stroke and other cardiovascular problems, a new government survey ... Health and Nutrition Examination Survey (NHANES) 1999-2006 shows that ...
... VA - The American Society of Pediatric Otolaryngology (ASPO) ... 2, during the 2010 Combined Otolaryngology Spring Meetings (COSM) ... Las Vegas, NV. During the ASPO meeting, ... scientific sessions featuring expert panelists will be presented focusing ...
... Readers are ... his interest and research on improving ones state of life. This book helps readers to ... strives to touch all walks of life. , ... Washington, D.C. (Vocus) April 26, 2010 -- Thomas Finn is ...
Cached Medicine News:Health News:Botulinum injection provides relief of tennis elbow 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 3Health News:Test Spots Potential Organ Donors Among Coma Patients 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 3Health News:Scientific meeting will host new research in children's ear, nose and throat health 2Health News:Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15 2
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
... VACUETTE® erythrocyte sedimentation rate analysers, which ... new generation unites the well-established advantages ... range of additional innovations which guarantee ... sedimentation rate. Cost effectiveness is an ...
... ESR analyzer that brings about ... pipettes. Up to 40 test ... or bach, with automated mixing. ... for back-up support or to ...
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: